Lexilium

Bromazepam, the active ingredient in Lexilium, is a benzodiazepine presented as an oral formulation for oral use. It is prescribed for the management of anxiety disorders and provides short‑term relief of anxiety symptoms in adult patients.

GNH USA supplies Lexilium as a licensed, GDP‑compliant international pharmaceutical product, providing reliable access to hospitals, pharmacies and clinics worldwide through validated supply chains, quality assurance processes and regulatory adherence. The company ensures each batch meets European pharmacopeial specifications and is packaged under strict temperature‑controlled conditions to preserve stability.

Bromazepam is an anxiolytic benzodiazepine used to manage conditions within the anxiety disorder spectrum. - Anxiety disorder: alleviates persistent excessive worry and associated physical symptoms. - Pre‑operative anxiety: provides short‑term calming before surgical procedures. - Acute stress reaction: reduces transient heightened anxiety during stressful events.

Bromazepam may be associated with a range of adverse reactions, which are classified by frequency and clinical significance.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: sensation of light‑headedness or loss of balance. - Impaired coordination: reduced motor control leading to clumsiness. - Memory impairment: difficulty recalling recent events.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that may require medical attention. - Paradoxical agitation: unexpected increase in anxiety, aggression, or hostility. - Dependence and withdrawal seizures: risk of physical dependence with abrupt discontinuation, potentially leading to seizures.

When prescribing or dispensing bromazepam, several safety considerations should be observed. - Assess renal and hepatic function: adjust use in patients with impairment. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. - Use caution in elderly: increased sensitivity to sedation and falls. - Avoid concomitant CNS depressants: risk of additive sedation. - Pregnancy and lactation: evaluate risk‑benefit, limited data available. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Bromazepam can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Other benzodiazepines: additive CNS depression – avoid concurrent use. - Opioids: risk of profound respiratory depression – avoid combination. - Alcohol: synergistic sedation – avoid consumption.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs): may increase sedation – monitor patient response. - Antihistamines: may enhance drowsiness – observe for excessive fatigue. - CYP3A4 inhibitors (e.g., erythromycin): may raise plasma levels – consider dose adjustment.